Companies › Roche
107 active drug programs in 852 registered trials: 464 Phase 2, 199 Phase 1, 158 Phase 3, 31 Phase 4; Oncology, Neurology, Ophthalmology, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Risdiplam (RO7034067) SMN2 pre-mRNA positive modulator | SMN2 | Phase 4 | Muscular Atrophy, Spinal; Spinal Muscular Atrophy (SMA) | Nov 2026 |
| Emicizumab Coagulation factor IX and X other | F9, F10 | Phase 4 | Severe Hemophilia A; Von Willebrand Disease, Type 3; Factor VIII Deficiency, Congenital; Hemophilia A Patient … | Nov 2026 |
| Faricimab Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor | ANGPT2, VEGFA | Phase 4 | Diabetic Macular Edema | Jan 2027 |
| Ocrelizumab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 4 | Relapsing Multiple Sclerosis; Progressive Multiple Sclerosis (PMS); Multiple Sclerosis; Multiple Sclerosis, Primary Progressive … | Sep 2027 |
| Faricimab Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor | ANGPT2, VEGFA | Phase 4 | Neovascular Age-related Macular Degeneration (nAMD); Wet Age-related Macular Degeneration; Diabetic Macular Edema; Macular Degeneration Choroidal Neovascularization … | Sep 2027 |
| Ocrelizumab (rHuPH20) B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 4 | Multiple Sclerosis | Feb 2029 |
| Atezolizumab Programmed cell death 1 ligand 1 inhibitor | CD274 | Phase 3 | Non-Small Cell Lung Cancer; Hepatocellular Carcinoma; Muscle-invasive Bladder Cancer; Unresectable Hepatocellular Carcinoma … | Nov 2026 |
| Tiragolumab T-cell immunoreceptor with Ig and ITIM domains inhibitor | TIGIT | Phase 3 | Hepatocellular Carcinoma; Cancer; Renal Cell Carcinoma; Rectal Neoplasms … | Nov 2026 |
| Inavolisib PI3-kinase p110-alpha subunit inhibitor | PIK3CA | Phase 3 | Breast Cancer; Metastatic Breast Cancer; Metastatic Castration-Resistant Prostate Cancer; PIK3CA-Mutated Cancers … | Nov 2026 |
| Satralizumab IL6Ralpha/GP130 antagonist | IL6R, IL6ST | Phase 3 | NMDAR Autoimmune Encephalitis; Neuromyelitis Optica Spectrum Disorder; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD); Duchenne Muscular Dystrophy … | Nov 2026 |
| Afimkibart Anti-integrin α4β7 monoclonal antibody | ITGA4, ITGB7, IL22RA1 | Phase 3 | Moderately to Severely Active Ulcerative Colitis; Moderately to Severely Active Crohns Disease; Crohns Disease; Atopic Dermatitis … | Dec 2026 |
| Crovalimab Complement C5 inhibitor | C5 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria; Atypical Hemolytic Uremic Syndrome | Jan 2027 |
| Alectinib ALK tyrosine kinase receptor inhibitor; Tyrosine-protein kinase receptor RET inhibitor; EML4-ALK inhibitor | ALK, RET, EML4 | Phase 3 | Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Solid Tumors; ALK Fusion-positive Solid or CNS Tumors … | Jan 2027 |
| Entrectinib (RXDX-101) Neurotrophic tyrosine kinase receptor inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor; ALK tyrosine kinase receptor inhibitor | NTRK1, NTRK2, NTRK3, ROS1, ALK | Phase 3 | Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Breast Cancer; Solid Tumors … | Jan 2027 |
| Glofitamab B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent | MS4A1, CD3E, CD3G, CD3D | Phase 3 | Lymphoma; Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma … | Jan 2027 |
| Ranibizumab Vascular endothelial growth factor A inhibitor | VEGFA | Phase 3 | Neovascular Age-related Macular Degeneration (nAMD); Neovascular Age-related Macular Degeneration; Diabetic Macular Edema; Neovascular Age-Related Macular Degeneration … | Feb 2027 |
| Cevostamab BCMA-directed bispecific antibody | BCMA | Phase 3 | Multiple Myeloma | Feb 2027 |
| Mosunetuzumab T cell surface glycoprotein CD3 binding agent; B-lymphocyte antigen CD20 binding agent | CD3E, CD3G, CD3D, MS4A1 | Phase 3 | Non-Hodgkin Lymphoma; Relapsed or Refractory Follicular Lymphoma; Lupus; B-cell Non-Hodgkin Lymphoma … | Feb 2027 |
| Polatuzumab vedotin B-cell antigen receptor complex-associated protein beta chain binding agent; Tubulin inhibitor | CD79B, Tubulin | Phase 3 | Non-Hodgkin Lymphoma; Large B-Cell Lymphoma; B-cell Non-Hodgkin Lymphoma; Non-Hodgkins Lymphoma … | Feb 2027 |
| Pertuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Solid Tumors | Mar 2027 |
| Trastuzumab Emtansine Receptor protein-tyrosine kinase erbB-2 binding agent; Tubulin inhibitor | ERBB2, Tubulin | Phase 3 | Breast Cancer; Ovarian Cancer; Metastatic Solid Tumor; Early Breast Cancer … | Mar 2027 |
| Enicepatide (RO7795068) Dual GLP-1/GIP receptor agonist | GLP1R, GIPR | Phase 3 | Obesity; Obesity or Overweight; Healthy Participants | Apr 2027 |
| Baloxavir marboxil Polymerase acidic protein inhibitor | INFLAV, PB2 | Phase 3 | Influenza, Human; Influenza; Influenza Disease; Flu; Hematopoietic and Lymphoid Cell Neoplasm | Apr 2027 |
| Fenebrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Relapsing Multiple Sclerosis; Multiple Sclerosis, Primary Progressive | Jun 2027 |
| Giredestrant Estrogen receptor alpha degrader | ESR1 | Phase 3 | Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer; Early Breast Cancer; Breast Cancer | Jun 2027 |
| Astegolimab IL-33 receptor (ST2) inhibitor | IL1RAP, IL33R | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD); Chronic Obstructive Pulmonary Disease | Jun 2027 |
| Bevacizumab Vascular endothelial growth factor A inhibitor | VEGFA | Phase 3 | Hepatocellular Carcinoma; Advanced Liver Cancers | Jul 2027 |
| Giredestrant Estrogen receptor alpha degrader | ESR1 | Phase 3 | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer; Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer; Locally Advanced or Metastatic Breast Cancer; Early Breast Cancer … | Jul 2027 |
| NXT007 Factor VIII mimetic/extended half-life factor VIII replacement | F8 | Phase 3 | Hemophilia A | Sep 2027 |
| Obinutuzumab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Childhood Idiopathic Nephrotic Syndrome; Primary Membranous Nephropathy; Systemic Lupus Erythematosus; Lupus Nephritis … | Dec 2027 |
| Trontinemab Anti-tau antibody targeting phosphorylated tau | MAPT | Phase 3 | Alzheimers Disease; Alzheimer's Disease | Feb 2028 |
| Ipatasertib Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 3 | Cancer; Ovarian Cancer; Solid Tumors; Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer … | Feb 2028 |
| Lurbinectedin DNA alkylating agent | – | Phase 3 | Small-Cell Lung Cancer | Feb 2028 |
| Sefaxersen (RO7434656) Antisense Oligonucleotide (ASO) therapy | – | Phase 3 | Primary IgA Nephropathy | May 2028 |
| Pegozafermin (BIO89-100) | – | Phase 3 | Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis | Jun 2028 |
| Petrelintide Dual GLP-1 and glucagon receptor agonist | GLP1R, GCGR | Phase 3 | Obesity or Overweight | Oct 2028 |
| Divarasib KRAS G12C inhibitor | KRAS | Phase 3 | Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Metastatic Colorectal Cancer | Nov 2028 |
| Prasinezumab Alpha-synuclein binding agent | SNCA | Phase 3 | Parkinson's Disease; Parkinsons Disease | Jun 2029 |
| Lenalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Relapsed or Refractory Follicular Lymphoma; Follicular Lymphoma | Dec 2029 |
| Mycophenolate Mofetil Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | IMPDH1, IMPDH2 | Phase 3 | Childhood Idiopathic Nephrotic Syndrome | – |
| Sorafenib Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | RAF1, PDGFRB, KIT, FLT3, BRAF | Phase 3 | Unresectable Hepatocellular Carcinoma; AML (Acute Myeloid Leukemia); Locally Advanced Thyroid Gland Carcinoma; Hepatocellular Carcinoma … | – |
| RO7204239 Anti-myostatin antibody | MSTN | Phase 2 | Facioscapulohumeral Muscular Dystrophy (FSHD); Spinal Muscular Atrophy (SMA); Obesity; Type 2 Diabetes Mellitus | Nov 2026 |
| RO7269162 BACE1 inhibitor | APP | Phase 2 | Alzheimer's Disease | Nov 2026 |
| Cobimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 2 | Non-small Cell Lung Cancer; Melanoma; Metastatic Distal Bile Duct Adenocarcinoma; Chronic Myelomonocytic Leukemia (CMML) … | Nov 2026 |
| Pralsetinib Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor | RET, CCDC6, KIF5B | Phase 2 | Non-small Cell Lung Cancer; Advanced Thyroid Cancer Patients Who Received Target Therapy; Lung Cancer Stage III | Nov 2026 |
| Vemurafenib Serine/threonine-protein kinase B-raf inhibitor | BRAF | Phase 2 | Non-small Cell Lung Cancer; Thyroid Gland Follicular Carcinoma; Colorectal Carcinoma; Hairy Cell Leukemia … | Nov 2026 |
| RO7795081 GLP-1/GIP receptor dual agonist | GIPR, GLP1R | Phase 2 | Type 2 Diabetes Mellitus; Overweight; Healthy Volunteers; Renal Impairment | Dec 2026 |
| Tobemstomig | – | Phase 2 | Renal Cell Carcinoma; Breast Cancer; Urothelial Cancer; Advanced Liver Cancers | Dec 2026 |
| Cobimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 2 | Non-Small Cell Lung Cancer; Ovarian Cancer | Jun 2027 |
| Trastuzumab Emtansine Receptor protein-tyrosine kinase erbB-2 binding agent; Tubulin inhibitor | ERBB2, Tubulin | Phase 2 | Neoplasm Metastasis | Jun 2027 |
| RO7837195 | – | Phase 2 | Ulcerative Colitis | Aug 2027 |
| Autogene Cevumeran TLR3 agonist | TLR3 | Phase 2 | Muscle-invasive Urothelial Carcinoma | Nov 2027 |
| Selnoflast selective NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome inhibito | – | Phase 2 | Atherosclerosis | Jan 2028 |
| Enzalutamide Androgen Receptor antagonist | AR | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | Mar 2028 |
| RO7268489 | – | Phase 2 | Progressive Multiple Sclerosis | May 2028 |
| RO7771950 HER2 tyrosine kinase inhibitor | – | Phase 2 | HER2-positive Breast Cancer | May 2029 |
| RO7568282 BACE inhibitor | – | Phase 2 | Alzheimer's Disease | Nov 2029 |
| RO7965032 unclear - complement C3 inhibitor | – | Phase 2 | Geographic Atrophy Secondary to Age-Related Macular Degeneration | Aug 2030 |
| Autogene cevumeran Personalized neoantigen vaccine | – | Phase 2 | Adenocarcinoma, Pancreatic Ductal | Jan 2031 |
| OpRegen Retinal pigment epithelium cell therapy | – | Phase 2 | Geographic Atrophy | Mar 2031 |
| Tominersen Huntingtin mRNA antisense inhibitor | HTT | Phase 2 | Huntington Disease | – |
| RO7497372 | – | Phase 1 | Diabetic Macular Edema | Nov 2026 |
| Cevostamab | – | Phase 1 | Multiple Myeloma; Relapsed or Refractory Multiple Myeloma; Lupus Erythematosus, Systemic | Nov 2026 |
| XmAb24306 Bispecific antibody | – | Phase 1 | Multiple Myeloma | Nov 2026 |
| RG6496 | – | Phase 1 | Huntington's Disease | Dec 2026 |
| RO7790121 anti-LOXL2 monoclonal antibody | – | Phase 1 | MASH | Dec 2026 |
| Belvarafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 1 | Melanoma; Primary Brain Tumor | Dec 2026 |
| Englumafusp alfa CD19-targeted 4-1BB ligand | CD19, TNFSF14 | Phase 1 | Lymphoma, Non-Hodgkin | Mar 2027 |
| RO7812653 | – | Phase 1 | Alzheimer's Disease | Mar 2027 |
| Runimotamab HER2-targeting bispecific antibody | ERBB2 | Phase 1 | Solid Tumors | Apr 2027 |
| RO7806881 | – | Phase 1 | Healthy Volunteers | May 2027 |
| RO7567132 | – | Phase 1 | Cancer-Neoplasms | May 2027 |
| RO7890597 | – | Phase 1 | Healthy Volunteers | Jun 2027 |
| RO7247669 Anti-PD-1 and anti-LAG-3 bispecific antibody | PDCD1, LAG3 | Phase 1 | Solid Tumors | Jun 2027 |
| RO7656594 | – | Phase 1 | Advanced Prostate Cancer | Jun 2027 |
| RO7121932 S1P1 receptor modulator | – | Phase 1 | Multiple Sclerosis | Jul 2027 |
| TPST-1120 TPS inhibitor | – | Phase 1 | Advanced Liver Cancers | Jul 2027 |
| Tocilizumab Interleukin-6 receptor alpha subunit inhibitor | IL6R | Phase 1 | Advanced Liver Cancers; Takayasu Arteritis; Primary Cutaneous Amyloidosis; Giant Cell Arteritis … | Jul 2027 |
| RO7126209 Anti-amyloid beta monoclonal antibody | APP | Phase 1 | Alzheimers Disease | Jul 2027 |
| ZN-A-1041 | – | Phase 1 | Advanced Solid Tumors | Aug 2027 |
| GDC-1261 | – | Phase 1 | Advanced Prostate Cancer | Nov 2027 |
| RO7507062 | – | Phase 1 | Systemic Lupus Erythematosus | Nov 2027 |
| GDC-1971 | – | Phase 1 | Non-Small Cell Lung Cancer | Dec 2027 |
| GDC-6036 KRAS G12C inhibitor | KRAS | Phase 1 | Non-Small Cell Lung Cancer | Dec 2027 |
| RO7663498 unclear - Roche code-named drug | – | Phase 1 | Diabetic Retinopathy | Jan 2028 |
| RO7566802 | – | Phase 1 | Locally Advanced Solid Tumors | Mar 2028 |
| GDC-7035 KRAS G12D inhibitor | KRAS | Phase 1 | Solid Tumor | May 2028 |
| Enzelkitug | – | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Jul 2028 |
| Iberdomide (CC-220) CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 1 | Multiple Myeloma; Non-Hodgkin Lymphoma | Jul 2028 |
| GDC-4198 FGFR1 inhibitor | FGFR1 | Phase 1 | Breast Cancer | Aug 2028 |
| RO7673396 RAS inhibitor | – | Phase 1 | Neoplasms | Aug 2028 |
| RO7830698 | – | Phase 1 | Chronic Obstructive Pulmonary Disease (COPD) | Oct 2028 |
| RO7823653 | – | Phase 1 | Diabetic Macular Edema | Nov 2028 |
| RO7875913 | – | Phase 1 | Healthy Volunteers | Jun 2030 |
| RO7851624 anti-TACSTD2 (TROP-2) antibody-drug conjugate | TACSTD2 | Phase 1 | Relapsed/Refractory Multiple Myeloma | Jul 2030 |
| SY-5609 | – | Phase 1 | Metastatic Colorectal Cancer | Aug 2030 |
| Ladiratuzumab Vedotin Tubulin inhibitor; Zinc transporter ZIP6 binding agent | Tubulin, SLC39A6 | Phase 1 | Metastatic Breast Cancer | Sep 2030 |
| Selicrelumab Tumor necrosis factor receptor superfamily member 5 agonist | CD40 | Phase 1 | Metastatic Breast Cancer | Sep 2030 |
| OpRegen Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells | – | Phase 1 | Age-Related Macular Degeneration | Jan 2031 |
| SPK-8011QQ (RO7878488) Gene therapy for Factor VIII deficiency | F8 | Phase 1 | Hemophilia A | Apr 2032 |
| P-CD19CD20-ALLO1 allogeneic CAR-T cell therapy targeting CD19 and CD20 | CD19, CD20 | Phase 1 | Multiple Sclerosis | Aug 2032 |
| 203Pb-DOTAM (RO7205834-009) Lead-203 labeled imaging surrogate for dosimetry assessment | – | Phase 1 | Metastatic Colorectal Cancer | Feb 2034 |
| 212Pb-DOTAM (RO7205834-010) Lead-212 labeled therapeutic radioligand for alpha-particle therapy | – | Phase 1 | Metastatic Colorectal Cancer | Feb 2034 |
| SPLIT Abs (RO7782304, RO7782306) CEA-targeting pretargeting antibody for radioimmunotherapy | CEACAM5 | Phase 1 | Metastatic Colorectal Cancer | Feb 2034 |
| SPK-10001 Gene therapy targeting huntingtin gene | HTT | Phase 1 | Huntington Disease | Jan 2035 |
| GDC-6988 Unclear - code-named drug | – | Phase 1 | Non-cystic Fibrosis Bronchiectasis | – |
| RO7763505 | – | Phase 1 | Stable Coronary Artery Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03179943 | Atezolizumab | Phase 2 | Urothelial Carcinoma | Oncology | Jul 2020 |
| NCT04650321 | Ocrelizumab | Phase 4 | Multiple Sclerosis | Neurology | Aug 2021 |
| NCT04300686 | Tocilizumab | Phase 4 | Takayasu Arteritis | Immunology | May 2022 |
| NCT03879577 | Trastuzumab Emtansine | Phase 2 | Breast Cancer | Oncology | Mar 2023 |
| NCT04941287 | Atezolizumab | Phase 2 | Metastatic Distal Bile Duct Adenocarcinoma | Oncology | Jan 2024 |
| NCT04941287 | Cobimetinib | Phase 2 | Metastatic Distal Bile Duct Adenocarcinoma | Oncology | Jan 2024 |
| NCT02486718 | Atezolizumab | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Jan 2024 |
| NCT03671018 | Mosunetuzumab | Phase 1 | B-cell Non-Hodgkin Lymphoma | Oncology | Jan 2024 |
| NCT03671018 | Polatuzumab vedotin | Phase 1 | B-cell Non-Hodgkin Lymphoma | Oncology | Jan 2024 |
| NCT04563338 | Atezolizumab | Phase 2 | Hepatocellular Carcinoma | Oncology | Jun 2024 |
| NCT04367311 | Atezolizumab | Phase 2 | Lung Cancer | Oncology | Aug 2024 |
| NCT05751343 | Atezolizumab | Phase 2 | Hepatocellular Carcinoma | Oncology | Aug 2024 |
| NCT03385655 | Ipatasertib | Phase 2 | Prostate Cancer | Oncology | Oct 2024 |
| NCT04980222 | Glofitamab | Phase 2 | Lymphoma | Oncology | Oct 2024 |
| NCT06482086 | Sorafenib | Phase 2 | Locally Advanced Thyroid Gland Carcinoma | Oncology | Dec 2024 |
| NCT04888221 | Tocilizumab | Phase 3 | Giant Cell Arteritis | Immunology | Jan 2025 |
| NCT04387734 | Ocrelizumab | Phase 4 | Relapsing Multiple Sclerosis | Neurology | Feb 2025 |
| NCT04166721 | Atezolizumab | Phase 1 | Metastatic Esophageal Cancer | Oncology | Mar 2025 |
| NCT06875245 | Faricimab | Phase 4 | Wet Age-related Macular Degeneration | Ophthalmology | Apr 2025 |
| NCT05548556 | RO7204239 | Phase 2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Neurology | May 2025 |
| NCT05904886 | Atezolizumab | Phase 3 | Hepatocellular Carcinoma | Oncology | May 2025 |
| NCT05904886 | Tiragolumab | Phase 3 | Hepatocellular Carcinoma | Oncology | May 2025 |
| NCT05904886 | Bevacizumab | Phase 3 | Hepatocellular Carcinoma | Oncology | May 2025 |
| NCT05781308 | Atezolizumab | Phase 2 | Non Small Cell Lung Cancer | Oncology | Jun 2025 |
| NCT04660344 | Atezolizumab | Phase 3 | Muscle-invasive Bladder Cancer | Oncology | Jun 2025 |
| NCT04289779 | Atezolizumab | Phase 2 | Bladder Cancer | Oncology | Jun 2025 |
| NCT04479267 | Polatuzumab vedotin | Phase 2 | Diffuse Large B-Cell Lymphoma | Oncology | Jun 2025 |
| NCT05595642 | Astegolimab | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | Respiratory | Jun 2025 |
| NCT05350592 | Tocilizumab | Phase 2 | Acute Myocardial Infarction | Cardiovascular | Jun 2025 |
| NCT05627557 | Obinutuzumab | Phase 3 | Childhood Idiopathic Nephrotic Syndrome | Genitourinary | Sep 2025 |
| NCT05627557 | Mycophenolate Mofetil | Phase 3 | Childhood Idiopathic Nephrotic Syndrome | Genitourinary | Sep 2025 |
| NCT04020809 | Atezolizumab | Phase 1 | Cutaneous Melanoma | Oncology | Oct 2025 |
| NCT06998875 | Tocilizumab | Phase 4 | Primary Cutaneous Amyloidosis | Metabolic and endocrine | Oct 2025 |
| NCT05174650 | Atezolizumab | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Dec 2025 |
| NCT05067348 | Tocilizumab | Phase 2 | Myasthenia Gravis, Generalized | Neurology | Dec 2025 |
| NCT03899428 | Sorafenib | Phase 2 | Hepatocellular Carcinoma | Oncology | Dec 2025 |
| NCT04680442 | Trastuzumab Emtansine | Phase 2 | Breast Cancer | Oncology | Dec 2025 |
| NCT06452537 | Tocilizumab | Phase 2 | Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease | Neurology | Jan 2026 |
| NCT04409639 | Cobimetinib | Phase 2 | Chronic Myelomonocytic Leukemia (CMML) | Oncology | Jan 2026 |
| NCT07439055 | Emicizumab | Phase 2 | Hemophilia A Patient | Hematology | Mar 2026 |
| NCT05689671 | Atezolizumab | Phase 4 | Non-Small Cell Lung Cancer Metastatic | Oncology | Mar 2026 |
| NCT05992220 | Atezolizumab | Phase 2 | Hepatocellular Carcinoma | Oncology | Mar 2026 |
| NCT03673787 | Atezolizumab | Phase 1 | Solid Tumor | Oncology | Mar 2026 |
| NCT03673787 | Ipatasertib | Phase 1 | Solid Tumor | Oncology | Mar 2026 |
| NCT05686551 | Tominersen | Phase 2 | Huntington Disease | Neurology | May 2026 |
| NCT06952452 | Ranibizumab | Phase 3 | Wet Age-related Macular Degeneration | Ophthalmology | Jul 2026 |
| NCT06603246 | GDC-6988 | Phase 1 | Non-cystic Fibrosis Bronchiectasis | Respiratory | Aug 2026 |
| NCT07285850 | Atezolizumab | Phase 2 | HCC - Hepatocellular Carcinoma | Oncology | Aug 2026 |
| NCT05498896 | Atezolizumab | Phase 2 | Triple Negative Breast Cancer | Oncology | Aug 2026 |
| NCT05498896 | Ipatasertib | Phase 2 | Triple Negative Breast Cancer | Oncology | Aug 2026 |
| NCT05092373 | Atezolizumab | Phase 1 | Advanced Breast Carcinoma | Oncology | Sep 2026 |
| NCT05805501 | Tiragolumab | Phase 2 | Renal Cell Carcinoma | Oncology | Oct 2026 |
| NCT05805501 | Tobemstomig | Phase 2 | Renal Cell Carcinoma | Oncology | Oct 2026 |
| NCT04770896 | Atezolizumab | Phase 3 | Unresectable Hepatocellular Carcinoma | Oncology | Oct 2026 |
| NCT04770896 | Sorafenib | Phase 3 | Unresectable Hepatocellular Carcinoma | Oncology | Oct 2026 |
| NCT05852691 | Tobemstomig | Phase 2 | Breast Cancer | Oncology | Oct 2026 |
| NCT06426160 | Tocilizumab | Phase 2 | Pancreatitis, Chronic | Gastroenterology | Oct 2026 |
| NCT03533283 | Atezolizumab | Phase 1 | Non-Hodgkins Lymphoma | Oncology | Oct 2026 |
| NCT03523858 | Ocrelizumab | Phase 3 | Progressive Multiple Sclerosis (PMS) | Neurology | Oct 2026 |
| NCT03533283 | Glofitamab | Phase 1 | Non-Hodgkins Lymphoma | Oncology | Oct 2026 |
The 60 nearest readouts of 852 trials; the rest in the app.
MS4A1 (5) ERBB2 (4) Tubulin (4) VEGFA (4) GLP1R (3) BRAF (3) KRAS (3) HTT (2) ALK (2) RET (2) GIPR (2) CD3E (2)
Pfizer Eli Lilly Beijing Biotech Novo Nordisk Novartis AbbVie AstraZeneca Shanghai Henlius Biotech Jiangsu HengRui Medicine Regeneron Pharmaceuticals
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.